All News

FDA ODAC Vote Indicates Benefit of Poziotinib Does Not Outweigh Risk for HER2 Exon 20 Ins+ NSCLC
September 26, 2022

The FDA’s Oncologic Drugs Advisory Committee voted against poziotinib as a treatment for patients with HER2 exon 20 insertion–mutated non–small cell lung cancer.

FDA’s ODAC Gives Negative Opinion on Continued Melphalan Flufenamide Approval for Relapsed/Refractory Myeloma
September 26, 2022

The FDA’s Oncologic Drugs Advisory Committee voted against continued use of melphalan flufenamide for the treatment of relapsed/refractory multiple myeloma.

Matthew Schabath, PhD, on COLORS Training for Oncologists Treating LGBTQ+ Individuals
September 26, 2022

At 2022 ASCO, Matthew Schabath, PhD, discussed the COLORS training designed to improve cultural sensitivity amongst oncologists treating patients within the LGBTQ+ community.

Amit Oza, MD, MBBS, FRCPC, Discusses Optimizing Treatment With PARP Inhibitors in Advanced Ovarian Cancer
September 26, 2022

PARP inhibitors like rucaparib should be considered to treat all kinds of patients, including those who have deleterious mutations and HIV, according to Amit Oza, MD, MBBS, FRCPC.

Chiara Cremolini, MD, PhD, Assesses Panitumumab Plus Triplet vs Doublet Chemotherapy in RAS/BRAF Wild-Type Metastatic CRC
September 25, 2022

Chiara Cremolini, MD, PhD, discussed results from the phase 3 TRIPLETE study of triplet chemotherapy plus panitumumab in previously untreated patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.

European Commission Approves Nivolumab/Relatlimab Combo for Treatment of Unresectable or Metastatic Melanoma
September 25, 2022

The European Commission based its approval of nivolumab/relatlimab for patients with a PD-L1 expression of less than 1% on the results of the phase 2/3 RELATIVITY-047 trial.

Recap: Efficacy and Safety of Seribantumab in NRG1 Fusion–Positive Cancers
September 24, 2022

One of the CRESTONE investigators, Tejas Patil, MD, assistant professor of medicine–medical oncology at the University of Colorado School of Medicine in Aurora, discussed seribantumab in previously treated patients with NRG1 fusion–positive tumors.

Catherine A. Shu, MD, Reviews Findings of Cohort A of the Phase 1 CHRYSALIS-2 Trial in Pretreated EGFR+ NSCLC
September 24, 2022

Catherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.

Amit Oza, MD, MBBS, FRCPC, Highlights the Benefit of Early Maintenance PARP Inhibitor Use in Ovarian Carcinoma
September 23, 2022

PARP inhibitors such as rucaparib appear to garner the most benefit in the early maintenance setting in patients with ovarian cancer who have less advanced disease and less heterogeneity, according to Amit Oza, MD, MBBS, FRCPC.

Doris K. Hansen, MD, Analyzes Real-World Experiences With Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
September 23, 2022

Doris K. Hansen, MD, discussed results of an efficacy analysis examining the BCMA-directed CAR T-cell therapy idecabtagene vicleucel in real-world treatment of patients with relapsed/refractory multiple myeloma.